Serif Biomedicines is a Cambridge, Massachusetts-based biotechnology company developing Modified DNA as a new therapeutic class. Founded in 2021 within Flagship Labs and emerged from stealth in April 2026, Serif combines chemically modified DNA with mRNA co-factors and lipid nanoparticles to enable programmable, redosable gene expression without altering the genome. The platform targets rare diseases and immune programming and is protected by more than 20 patent families.
1
Round
5
Tags
Apr 21, 2026
Latest raise
Funding activity · 1 round
Apr 21, 2026
$50M
Series A
Led by Flagship Pioneering
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
